Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07594093

Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity

This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity.

The study is looking at:

* What side effects REGN20934 might cause * How much REGN20934 is in the blood at different times * If the body makes antibodies to REGN20934

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Overweight or Obesity Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

California Clinical Trials Medical Group

Glendale, California, 91206, United States

Location status: Recruiting

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Has a Body Mass Index (BMI) 25 to 35 kg/m^2
  • Females must be of non-childbearing potential

Key Exclusion Criteria:

  • A self-reported change of body weight >5 kg within approximately 90 days of visit 2
  • History of type 1 or type 2 diabetes
  • History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease, as defined in the protocol

Note: Other protocol defined inclusion/exclusion criteria apply

Treatment and study plan

REGN20934

Drug

Administered per the protocol

Placebo

Drug

Administered per the protocol

Primary outcomes

  1. Occurrence of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 16 weeks

  2. Severity of TEAEs

    Time frame: Up to 16 weeks

Secondary outcomes

  1. REGN20934 concentration in serum

    Time frame: Up to 16 weeks

  2. Occurrence of Anti-Drug Antibodies (ADAs) to REGN20934

    Time frame: Up to 16 weeks

  3. Magnitude of ADAs to REGN20934

    Time frame: Up to 16 weeks

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical Trials Administrator

CONTACT

[email protected]

844-734-6643

Sponsors and collaborators

Lead sponsor

Regeneron Pharmaceuticals

Industry

Registry information

Official study title

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of REGN20934 in Adult Participants With Overweight or Obesity

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
May 18, 2026
Registry last updated
Jul 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.